This article is provided for educational and informational purposes only. It does not constitute legal, financial, or tax advice, and no attorney-client relationship is formed by reading it. Laws, regulations, official guidance, and related information vary by jurisdiction, change frequently, and may have changed or become outdated since the publication date. Always verify current information with authoritative sources and consult a qualified professional about your specific circumstances. The author and publisher assume no liability for actions taken based on this information.
Key Facts
- Federal level: Marijuana is not broadly legal under federal law as of August 8, 2026.
- Federal level: A final rule effective April 28, 2026 placed FDA-approved marijuana products and marijuana subject to a state medical marijuana license in Schedule III.
- Federal level: Marijuana outside those medical categories generally remains in Schedule I, including marijuana used under state adult-use laws.
- Federal and state: Permission under state cannabis law does not by itself authorize conduct under federal law.
- Federal level: A separate proposal to move marijuana more broadly to Schedule III remained a rulemaking matter after hearings held in summer 2026; a proposal is not a final rule.
Marijuana has not been legalized across the United States by federal law. The current answer is more precise than a simple yes or no, however. Federal regulators moved defined medical categories to Schedule III in April 2026, while marijuana outside those categories generally remains a Schedule I controlled substance.
State legalization and federal scheduling operate on separate tracks. A state can remove its own penalties and license medical or adult-use businesses, but it cannot rewrite the federal Controlled Substances Act. The result is a continuing federal-state divide, with different consequences depending on the product, license, activity, and location.
What changed federally in April 2026
On April 28, 2026, a Department of Justice final rule placed two important categories in Schedule III: marijuana contained in an FDA-approved drug product and marijuana subject to a state-issued license for medical marijuana. The rule also covers specified marijuana extracts and naturally derived delta-9 THC within those categories.
The change took effect immediately. It was narrower than nationwide legalization and narrower than moving every form of marijuana to Schedule III. The rule expressly states that marijuana outside an FDA-approved product or a state medical marijuana license remains in Schedule I.
Schedule III is still a controlled-substance classification. Handling covered products remains subject to federal registration, security, recordkeeping, prescription, import-export, and other requirements. State licensing alone does not remove every federal condition attached to manufacturing, distributing, dispensing, or possessing a controlled substance.
Recreational marijuana remains federally prohibited
The 2026 medical rule did not move state-licensed adult-use marijuana to Schedule III. The Controlled Substances Act generally prohibits unauthorized manufacture, distribution, dispensing, and possession with intent to distribute a controlled substance. Marijuana-specific federal penalties also remain in the statute.
This creates the familiar policy gap. A state may allow an adult to possess or buy marijuana under state law, yet the same conduct may remain unauthorized under federal law. State legalization prevents prosecution under the relevant state prohibition; it does not create a nationwide exemption from the federal statute.
Federal consequences can arise in settings governed directly by federal law, including federal property, immigration, firearms, federal employment, federally regulated transportation, and some benefit or housing programs. Each field has its own statutes and rules, so the existence and effect of a consequence cannot be inferred from cannabis scheduling alone.
Schedule III is not the same as legalization
Legalization generally means removing a legal prohibition for defined conduct. Rescheduling changes the regulatory category of a controlled substance but leaves the Controlled Substances Act in place. Schedule III substances may be lawfully handled only through authorized channels.
The distinction is especially important for ordinary retail marijuana. A product does not become federally lawful merely because it is described as medical, recommended by a practitioner, or sold in a state-licensed store. The precise terms of the April 2026 rule, the state medical license, DEA registration, and other federal requirements all matter.
FDA law remains another layer. The Food and Drug Administration regulates drugs, foods, dietary supplements, and other consumer products under statutes separate from the Controlled Substances Act. A scheduling change does not automatically approve a product as safe and effective for a medical use or permit it to be marketed in food or as a supplement.
Hemp follows a different federal definition
Federal law distinguishes marijuana from hemp. Hemp that meets the applicable statutory definition is excluded from the Controlled Substances Act definition of marijuana, but hemp products can still be regulated under food, drug, agriculture, consumer-protection, and state laws.
Congress changed the federal hemp definition in legislation enacted in November 2025. The new definition, based in part on total THC concentration rather than only delta-9 THC concentration, is scheduled to take effect on November 12, 2026. Until that effective date, the currently operative definition remains the relevant federal line.
Calling a product “hemp” or “CBD” does not settle its legal status. Its composition, effective statutory definition, intended use, labeling, and the law governing the product category can all change the analysis.
The broader rescheduling process is separate
DOJ proposed in May 2024 to move marijuana more generally from Schedule I to Schedule III. After earlier proceedings were withdrawn, a new formal hearing process began in June 2026. DEA’s public docket lists post-hearing steps, which confirms the difference between an active proposal and an effective final rule.
Even a broader Schedule III rule would not automatically legalize recreational manufacture, sale, or possession. Controlled substances in Schedule III remain regulated, and marijuana-specific statutory provisions can continue to apply unless Congress changes them. The precise text and effective date of any future final action would control.
This is also an Administrative Procedure Act issue: proposed rules, hearings, final orders, and effective dates mark different stages of agency action. News that an administration supports rescheduling is not the same as an operative legal change.
How to interpret a federal legalization claim
A reliable claim should identify the category of cannabis, the governing federal provision, the state-law status, and the date. “Medical marijuana is Schedule III” is incomplete without the qualifications in the April 2026 final rule. “Marijuana is legal in this state” describes state law, not necessarily federal authorization.
As of August 8, 2026, the clearest summary is that federal law recognizes a limited Schedule III pathway for FDA-approved and state-licensed medical marijuana, while other marijuana generally remains in Schedule I and broader rescheduling remains unfinished. That is a significant policy change, but it is not federal legalization of marijuana.
Sources
- DOJ final rule on FDA-approved and state-licensed medical marijuana
- DEA proposed marijuana rescheduling docket
- 21 U.S.C. § 812, controlled-substance schedules
- 21 U.S.C. § 841, prohibited acts and penalties
- Congressional Research Service, legal consequences of rescheduling marijuana
- FDA regulation of cannabis and cannabis-derived products
